Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
IBC-DDT

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 26 May 2006:
Vol. 312. no. 5777, pp. 1228 - 1230
DOI: 10.1126/science.1126100
Prev | Table of Contents | Next

Reports

Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene

Outi Vierimaa,1* Marianthi Georgitsi,3* Rainer Lehtonen,3 Pia Vahteristo,3 Antti Kokko,3 Anniina Raitila,3 Karoliina Tuppurainen,4 Tapani M. L. Ebeling,2 Pasi I. Salmela,2 Ralf Paschke,5 Sadi Gündogdu,6 Ernesto De Menis,7 Markus J. Mäkinen,4 Virpi Launonen,3 Auli Karhu,3 Lauri A. Aaltonen3{dagger}

Pituitary adenomas are common in the general population, and understanding their molecular basis is of great interest. Combining chip-based technologies with genealogy data, we identified germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene in individuals with pituitary adenoma predisposition (PAP). AIP acts in cytoplasmic retention of the latent form of the aryl hydrocarbon receptor and also has other functions. In a population-based series from Northern Finland, two AIP mutations account for 16% of all patients diagnosed with pituitary adenomas secreting growth hormone and for 40% of the subset of patients who were diagnosed when they were younger than 35 years of age. Typically, PAP patients do not display a strong family history of pituitary adenoma; thus, AIP is an example of a low-penetrance tumor susceptibility gene.

1 Department of Clinical Genetics, Oulu University Hospital, 90029 Oulu, Finland.
2 Department of Internal Medicine, Oulu University Hospital, 90029 Oulu, Finland.
3 Department of Medical Genetics, Molecular and Cancer Biology Research Program, 00014 University of Helsinki, Helsinki, Finland.
4 Department of Pathology, University of Oulu, 90014 Oulu, Finland.
5 Medical Department III, Leipzig University, 04103 Leipzig, Germany.
6 Division of Endocrinology-Metabolism and Diabetes, Cerrahpasa Medical Faculty, University of Istanbul, 34303 Istanbul, Turkey.
7 Department of Internal Medicine, General Hospital, 31100 Treviso, Italy.

* These authors contributed equally to this work.

{dagger} To whom correspondence should be addressed. E-mail: lauri.aaltonen{at}helsinki.fi

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas.
C. A. Leontiou, M. Gueorguiev, J. van der Spuy, R. Quinton, F. Lolli, S. Hassan, H. S. Chahal, S. C. Igreja, S. Jordan, J. Rowe, et al. (2008)
J. Clin. Endocrinol. Metab. 93, 2390-2401
   Abstract »    Full Text »    PDF »
Update in Pituitary Disease.
S. Melmed (2008)
J. Clin. Endocrinol. Metab. 93, 331-338
   Abstract »    Full Text »    PDF »
Deletion of the Aryl Hydrocarbon Receptor-associated Protein 9 Leads to Cardiac Malformation and Embryonic Lethality.
B. C. Lin, R. Sullivan, Y. Lee, S. Moran, E. Glover, and C. A. Bradfield (2007)
J. Biol. Chem. 282, 35924-35932
   Abstract »    Full Text »    PDF »
Blood-derived gene-expression profiling in unravelling susceptibility to recessive disease.
P Vahteristo, A Kokko, O Saksela, K Aittomaki, and L A Aaltonen (2007)
J. Med. Genet. 44, 718-720
   Abstract »    Full Text »    PDF »
The clinical, pathological, and genetic features of familial isolated pituitary adenomas.
A. Beckers and A. F Daly (2007)
Eur. J. Endocrinol. 157, 371-382
   Abstract »    Full Text »    PDF »
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene.
L. A Naves, A. F Daly, J.-F. Vanbellinghen, L. A Casulari, C. Spilioti, A. V Magalhaes, M. F Azevedo, L. A Giacomini, P. P Nascimento, R. O Nunes, et al. (2007)
Eur. J. Endocrinol. 157, 383-391
   Abstract »    Full Text »    PDF »
No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia.
A Raitila, M Georgitsi, A Karhu, K Tuppurainen, M J Makinen, K Birkenkamp-Demtroder, K Salmenkivi, T F Orntoft, J Arola, V Launonen, et al. (2007)
Endocr. Relat. Cancer 14, 901-906
   Abstract »    Full Text »    PDF »
Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia.
M. Georgitsi, A. Raitila, A. Karhu, R. B. van der Luijt, C. M. Aalfs, T. Sane, O. Vierimaa, M. J. Makinen, K. Tuppurainen, R. Paschke, et al. (2007)
J. Clin. Endocrinol. Metab. 92, 3321-3325
   Abstract »    Full Text »    PDF »
CanPredict: a computational tool for predicting cancer-associated missense mutations.
J. S. Kaminker, Y. Zhang, C. Watanabe, and Z. Zhang (2007)
Nucleic Acids Res. 35, W595-W598
   Abstract »    Full Text »    PDF »
Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas.
L. Cazabat, R. Libe, K. Perlemoine, F. Rene-Corail, N. Burnichon, A.-P. Gimenez-Roqueplo, L. Dupasquier-Fediaevsky, X. Bertagna, E. Clauser, P. Chanson, et al. (2007)
Eur. J. Endocrinol. 157, 1-8
   Abstract »    Full Text »    PDF »
Phosphodiesterase 2A Forms a Complex with the Co-chaperone XAP2 and Regulates Nuclear Translocation of the Aryl Hydrocarbon Receptor.
S. K. de Oliveira, M. Hoffmeister, S. Gambaryan, W. Muller-Esterl, J. A. Guimaraes, and A. P. Smolenski (2007)
J. Biol. Chem. 282, 13656-13663
   Abstract »    Full Text »    PDF »
Aryl Hydrocarbon Receptor Interacting Protein and Pituitary Tumorigenesis: Another Interesting Protein.
S. Melmed (2007)
J. Clin. Endocrinol. Metab. 92, 1617-1619
   Full Text »    PDF »
Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families.
A. F. Daly, J.-F. Vanbellinghen, S. K. Khoo, M.-L. Jaffrain-Rea, L. A. Naves, M. A. Guitelman, A. Murat, P. Emy, A.-P. Gimenez-Roqueplo, G. Tamburrano, et al. (2007)
J. Clin. Endocrinol. Metab. 92, 1891-1896
   Abstract »    Full Text »    PDF »
Mutations in the Aryl Hydrocarbon Receptor Interacting Protein Gene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas.
A. Barlier, J.-F. Vanbellinghen, A. F. Daly, M. Silvy, M.-L. Jaffrain-Rea, J. Trouillas, G. Tamagno, L. Cazabat, V. Bours, T. Brue, et al. (2007)
J. Clin. Endocrinol. Metab. 92, 1952-1955
   Abstract »    Full Text »    PDF »
Germline Mutation in the Aryl Hydrocarbon Receptor Interacting Protein Gene in Familial Somatotropinoma.
R. A. Toledo, D. M. Lourenco Jr., B. Liberman, M. B. C. Cunha-Neto, M. G. Cavalcanti, C. B. Moyses, S. P. A. Toledo, and P. L. M. Dahia (2007)
J. Clin. Endocrinol. Metab. 92, 1934-1937
   Abstract »    Full Text »    PDF »
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update.
A. Karhu and L. A. Aaltonen (2007)
Hum. Mol. Genet. 16, R73-R79
   Abstract »    Full Text »    PDF »
Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis.
S. A. Boikos and C. A. Stratakis (2007)
Hum. Mol. Genet. 16, R80-R87
   Abstract »    Full Text »    PDF »
Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.
M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M. J. Makinen, O. Vierimaa, R. Paschke, W. Saeger, R. B. van der Luijt, T. Sane, et al. (2007)
PNAS 104, 4101-4105
   Abstract »    Full Text »    PDF »
Incidence and familial risks in pituitary adenoma and associated tumors.
K. Hemminki, A. Forsti, and J. Ji (2007)
Endocr. Relat. Cancer 14, 103-109
   Abstract »    Full Text »    PDF »
Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms.
J. S. Kaminker, Y. Zhang, A. Waugh, P. M. Haverty, B. Peters, D. Sebisanovic, J. Stinson, W. F. Forrest, J. F. Bazan, S. Seshagiri, et al. (2007)
Cancer Res. 67, 465-473
   Abstract »    Full Text »    PDF »
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium.
A. F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M. A. Tichomirowa, and A. Beckers (2006)
J. Clin. Endocrinol. Metab. 91, 4769-4775
   Abstract »    Full Text »    PDF »
Aryl Hydrocarbon Receptor Interacting Protein Variants in Sporadic Pituitary Adenomas.
R. Yu, V. Bonert, I. Saporta, L. J. Raffel, and S. Melmed (2006)
J. Clin. Endocrinol. Metab. 91, 5126-5129
   Abstract »    Full Text »    PDF »
Role of Endogenous XAP2 Protein on the Localization and Nucleocytoplasmic Shuttling of the Endogenous Mouse Ahb-1 Receptor in the Presence and Absence of Ligand.
R. S. Pollenz, S. E. Wilson, and E. J. Dougherty (2006)
Mol. Pharmacol. 70, 1369-1379
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)